<button id="eiezk"><video id="eiezk"></video></button>

產(chǎn)品名稱

Voriconazole - Vfend | UK 109496

產(chǎn)品貨號(hào)

Axon 2044 CAS [137234-62-9] MF C16H14F3N5OMW 349.31 Purity: 99% Optical purity: Optically pure Soluble in DMSO Description Orally bioavailable CYP51 inhibitor; Antifungal agent; Voriconazole binds and inhibits ergosterol synthesis by inhibiting CYP450-dependent 14-α sterol demethylase (CYP51, P450-DM), resulting in a depletion of ergosterol in fungal cell membrane. References Certificates Categories Extra info L.J. Scott et al. Voriconazole : a review of its use in the management of invasive fungal infections. Drugs. 2007, 67, 269-298. ? M. Sandherr et al. Pharmacology and metabolism of voriconazole and Posaconazole in the treatment of invasive aspergillosis: review of the literature. Eur. J. Med. Res. 2011, 16, 139-144. Certificate of Analysis Material Safety Data Sheet Cell Signaling & Oncology Diabetes & Metabolism Immunology EC 1.14.13.70 Cytochrome P450 Pfizer Licensed Products Orally bioavailable CYP51 inhibitor; Antifungal agent Chemical name (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol Source information Pfizer compound; Sold for research purposes under agreement from Pfizer Inc. Parent CAS No. [137234-62-9] Order Size Unit Price Stock 10 mg €95.00 In Stock

產(chǎn)品價(jià)格

現(xiàn)貨詢價(jià)，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

Voriconazole - Vfend | UK 109496

Based on 8 reference(s) in Google Scholar 9 10 8

Axon 2044

CAS [137234-62-9]

MF C16H14F3N5O
MW 349.31

Purity: 99%
Optical purity: Optically pure
Soluble in DMSO

Voriconazole

Description

Orally bioavailable CYP51 inhibitor; Antifungal agent; Voriconazole binds and inhibits ergosterol synthesis by inhibiting CYP450-dependent 14-α sterol demethylase (CYP51, P450-DM), resulting in a depletion of ergosterol in fungal cell membrane.

L.J. Scott et al. Voriconazole : a review of its use in the management of invasive fungal infections. Drugs. 2007, 67, 269-298.

M. Sandherr et al. Pharmacology and metabolism of voriconazole and Posaconazole in the treatment of invasive aspergillosis: review of the literature. Eur. J. Med. Res. 2011, 16, 139-144.

Certificate of Analysis
Material Safety Data Sheet

Cell Signaling & Oncology Diabetes & Metabolism Immunology EC 1.14.13.70 Cytochrome P450 Pfizer Licensed Products

Orally bioavailable CYP51 inhibitor; Antifungal agent

Chemical name

(2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol

Source information

Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

Parent CAS No.

[137234-62-9]

產(chǎn)品資料

<button id="eiezk"><video id="eiezk"></video></button>